孟鲁司特钠辅助治疗急性加重期慢性阻塞性肺疾病的疗效及炎症因子的影响

Effect of adjuvant montelukast sodium on inflammatory factors in patients with acute exacerbation of chronic obstructive pulmonary disease

目的 观察孟鲁司特钠辅助治疗对急性加重期慢性阻塞性肺疾病(COPD)的疗效及血清C反应蛋白(CRP)和降素钙原(PCT)水平的影响。方法 70例急性加重期COPD患者随机分为对照组和实验组,对照组实施常规治疗,实验组增加孟鲁司特钠辅助治疗。观察两组治疗效果及CRP、PCT、肺功能变化。结果 实验组疗效明显优于对照组;两组治疗后的血清CRP及PCT水平均低于治疗前,以实验组更显著(P<0.05或0.01)。两组患者各项肺功能指标比较差异无统计学意义(P>0.05)。结论 孟鲁司特钠可提高急性加重期COPD患者治疗效果,降低炎症因子水平。

Objective To observe the effect of adjuvant montelukast sodium on serum C-reaction protein(CRP) and procalcitonin(PCT) levels in patients with acute exacerbation of chronic obstructive pulmonary disease(AE-COPD). Methods Seventy patients with AE-COPD were randomly treated with conventional therapy(control group) or adjuvant montelukast sodium(experimental group). Clinical efficacy, CRP, PCT, and pulmonary function were compared between two groups.Results The clinical efficacy was better in experimental group than in control group. Serum CRP and PCT levels were lower after therapy in two groups, especially in experimental group(P<0.01 or 0.05). There was no significant difference in pulmonary function between two groups(P>0.05). Conclusion Montelukast sodium can improve the efficacy and reduce inflammatory factors in AE-COPD patients.